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Abstract
Background: The transient receptor potential ankyrin 1 (TRPA1) is a calcium-permeable cation channel that is
expressed on capsaicin-sensitive sensory neurons, endothelial and inflammatory cells. It is activated by a variety of
inflammatory mediators, such as methylglyoxal, formaldehyde and hydrogen sulphide. Since only few data are
available about the role of TRPA1 in arthritis and related pain, we investigated its involvement in inflammation
models of different mechanisms.
Methods: Chronic arthritis was induced by complete Freund’s adjuvant (CFA), knee osteoarthritis by monosodium
iodoacetate (MIA) in TRPA1 knockout (KO) mice and C57Bl/6 wildtype mice. For comparison, carrageenan- and
CFA-evoked acute paw and knee inflammatory changes were investigated. Thermonociception was determined on
a hot plate, cold tolerance in icy water, mechanonociception by aesthesiometry, paw volume by plethysmometry,
knee diameter by micrometry, weight distribution with incapacitance tester, neutrophil myeloperoxidase activity
and vascular leakage by in vivo optical imaging, and histopathological alterations by semiquantitative scoring.
Results: CFA-induced chronic mechanical hypersensitivity, tibiotarsal joint swelling and histopathological alterations,
as well as myeloperoxidase activity in the early phase (day 2), and vascular leakage in the later stage (day 7), were
significantly reduced in TRPA1 KO mice. Heat and cold sensitivities did not change in this model. Although in
TRPA1 KO animals MIA-evoked knee swelling and histopathological destruction were not altered, hypersensitivity
and impaired weight bearing on the osteoarthritic limb were significantly decreased. In contrast, carrageenan- and
CFA-induced acute inflammation and pain behaviours were not modified by TRPA1 deletion.
Conclusions: TRPA1 has an important role in chronic arthritis/osteoarthritis and related pain behaviours in the
mouse. Therefore, it might be a promising target for novel analgesic/anti-inflammatory drugs.
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Background
Chronic arthritis is one of the greatest health problems
worldwide due to its high prevalence and insufficient
therapeutic outcomes [1, 2]. Pain is the key complaint
for arthritic patients, but its precise mechanism is poorly
understood and its treatment is also a great unresolved
problem. The currently used analgesics are often inef-
fective or their long-term use induces severe adverse
effects [3–5]. Therefore, there is a pressing need to
understand the pathomechanisms of arthritis-related
pain and identify more effective pharmacological targets
for analgesia. Investigation of the regulatory role and ac-
tivation mechanisms of peptidergic sensory nerves and
the complexity of neuro-immune interactions in this
condition can be a promising research area [6–9].
Transient receptor potential ankyrin 1 (TRPA1) is a
calcium-permeable non-selective cation channel pre-
dominantly expressed on capsaicin-sensitive primary
sensory neurons, co-localized with the transient receptor
potential vanilloid 1 (TRPV1) receptor in over 90 % of
these cells [10, 11]. Besides the nociceptors, functional
TRPA1 has also been described on non-neuronal cells,
such as keratinocytes [12], fibroblasts [13], synoviocytes
[14], macrophages [15, 16], lymphocytes [17], thymo-
cytes [17] and endothelial cells [18] suggesting its com-
plex involvement in inflammatory mechanisms. TRPA1
was characterized originally as a noxious cold- (<17 °C)
activated channel [11], although its function in cold sen-
sation is still a matter of debate. Several studies showed
that TRPA1 is not required for normal cold sensitivity
[19, 20], but others suggest that it acts as a major sensor
for noxious cold [20], contributes to cold nociception
and cold hypersensitivity after inflammation and nerve
injury [21–23]. TRPA1 is also directly stimulated by
intracellular calcium [24] and a broad range of noxious
endogenous oxidative products, such as 4-hydroxy-2-
nonenal, hydrogen peroxide, hypochloride, hydrogen
sulphide, 15-delta prostaglandin J2 [25–28]. Further-
more, there are several exogenous irritants like mustard
oil (allyl isothiocyanate: AITC) [29], cinnamaldehyde
[30, 31], allicin [32, 33] and formalin [34] that are known
to be potent agonists of TRPA1. Inflammatory media-
tors, such as bradykinin and serotonin, can sensitize this
receptor and increase the responsiveness of the nerve
endings [19, 35]. These findings suggest that TRPA1
may be involved in the development and maintenance of
arthritic pain, but the precise mechanisms are still
unknown.
Few data are available on the involvement of this
receptor in inflammation and pain. Previously, some
studies showed the role of TRPA1 in nociceptive pro-
cesses in vivo using selective antagonists of the receptor.
The pharmacological blockade of TRPA1 using intra-
plantar injection of AP-18 24 hours after complete
Freund’s adjuvant (CFA) injection and intraplantar, intra-
peritoneal or intrathecal administration of HC-030031 1,
7 and 28 days after the administration of the adjuvant
significantly attenuated mechanical hypersensitivity in
mice and cold hypersensitivity in rats [36, 37]. Oral
HC-030031 significantly reversed mechanical hyper-
sensitivity in the CFA model of inflammatory pain at
the 24-hour time point and the spinal nerve ligation
model of neuropathic pain in rats 6 weeks post surgery
[38]. HC-030031 given intraperitoneally or orally sig-
nificantly reduced formalin- and AITC-evoked nocifensive
behaviours [34, 38]. Its intraplantar administration
prevented and reversed carrageenan-induced mechanical
hypersensitivity in rats [10], inhibited AITC- and carra-
geenan-induced paw oedema in mice at the 3- and 6-
hour time point [39]. In the monosodium iodoacetate
(MIA)-induced osteoarthritis (OA) model systemic or
intra-articular HC-030031 failed to block weight asym-
metry and ongoing pain at the 1-hour time point [40], sys-
temic injection of another TRPA1-antagonist, A-967079,
reduced the evoked neuronal responses to high-intensity
mechanical stimulation, but did not alter their spontan-
eous firing in osteoarthritic animals [41].
Although TRPA1-deficient mice are also valuable tools
to investigate the role of this receptor in vivo, only few
arthritis studies have been performed with these. Two
articles reported that TRPA1 knockout (KO) mice did
not develop acute pain, thermal or mechanical hyper-
sensitivity after intraplantar injection of bradykinin or
AITC, but displayed reduced sensitivity to intense cold
and punctate mechanical stimulation [19, 23]. In con-
trast, one study showed that TRPA1 KO mice exhibited
mechanical hypersensitivity 24 hours following CFA
injection [36]. In a chronic model of inflammatory pain
induced by intra-articular CFA, in TRPA1 KO mice
mechanical hypersensitivity developed only 24 hours
after CFA administration, but it was significantly smaller
than in the wildtypes during the whole 4-week period
[42]. TRPA1-deficient mice displayed attenuated carra-
geenan- and AITC-induced acute inflammatory paw
oedema at the 3- and 6-hour time point [39]. The age-
dependent role for TRPA1 in pain behaviour occurring
in the adjuvant-induced arthritis model has very recently
been revealed: old (>18 months old) TRPA1 KO mice
developed significantly lower mechanical hypersensitivity
as compared to their wildtypes throughout the 8-week
experimental period, while the young (3–6 months old)
TRPA1-deficient ones revealed that only during the first
2 weeks [43].
There are only few data regarding the role of TRPA1
in inflammation and pain, there are no knockout studies
providing evidence for its precise role in chronic inflam-
matory pain processes in various time points, except for
one article [42]. Therefore, in the present study, we
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aimed to analyze its involvement in chronic arthritis of
different mechanisms and related nociception in com-
parison with acute models using TRPA1-deficient mice.
Methods
Ethics statement
All experimental procedures were carried out according
to the 1998/XXVIII Act of the Hungarian Parliament
on Animal Protection and Consideration Decree of
Scientific Procedures of Animal Experiments (243/1988),
complied with the recommendations of the International
Association for the Study of Pain (IASP). The studies were
approved by the Ethics Committee on Animal Research of
the University of Pécs (licence number: BA 02/2000–2/
2012).
Experimental animals
Experiments were carried out on male and female
TRPA1-deficient mice (TRPA1 KO) and their wildtype
(WT) counterparts (8–12 weeks, 20–30 g). Hetero-
zygous TRPA1-deleted mice generated on the C57Bl/6
background were kindly donated by Pierangelo Geppetti
(University of Florence, Italy). These mice were gener-
ated and characterized as described in detail in earlier
publications [19, 23]. They were bred and kept in
the Laboratory Animal House of the Department of
Pharmacology and Pharmacotherapy of the University of
Pécs at 24–25 °C, provided with standard mouse chow
and water ad libitum and maintained under a 12-hour
light–dark cycle. Each mouse genotype was confirmed by
PCR analysis.
CFA-induced chronic inflammatory pain model
The chronic joint inflammation was induced by intra-
plantar injection of complete Freund’s adjuvant (CFA,
heat-killed Mycobacterium tuberculosis suspended in
paraffin oil, 1 mg/ml; Sigma-Aldrich, St. Louis, MO,
USA) into the right hindpaw and subcutaneously (s.c.)
into the tail root (50–50 μl). An additional s.c. injection
was administered on the following day into the tail root
(50 μl) in order to potentiate the systemic effects.
Measurements were performed throughout the 21-day
experimental period. In mice, this injection paradigm
induces a chronic arthritis in the tibiotarsal joint on
the injection side transiently accompanied by mild
systemic symptoms in the early phase, such as weight
loss, fever and spontaneous motility decrease. How-
ever, arthritic symptoms do not develop in the contra-
lateral hindlimb [44].
MIA-induced osteoarthritis model
Mice were anaesthetized with intraperitoneally (i.p.) ad-
ministered ketamine-xylazine (100/10 mg/kg). Osteoarth-
ritis was induced by an injection of 20 μl, 25 mg/ml
monosodium iodoacetate (MIA, Sigma-Aldrich, St. Louis,
MO, USA) in 0.9 % saline into the left knee joint cavity
through the patellar ligament. Measurements were per-
formed throughout the 21-day experimental period [45].
Carrageenan-induced acute inflammatory pain model
Acute paw inflammation was evoked by intraplantar in-
jection of 3 % carrageenan (dissolved in 0.9 % sodium
chloride , Sigma-Aldrich, St. Louis, MO, USA) into the
right hindpaw (50 μl). Measurements were performed
throughout the 24-hour experimental period [46].
CFA-induced acute inflammatory pain model
Mice were anaesthetized with i.p. ketamine-xylazine
(100/10 mg/kg). For induction of joint inflammation, the
knees of mice were injected intra-articularly with 20 μl
CFA (Sigma-Aldrich, St. Louis, MO, USA) into the right
knee joint and 20 μl saline (0.9 % sodium chloride) into
the left knee joint. Measurements were carried out over
a period of 24 hours [42].
Measurement of mechanical hypersensitivity
Mechanical sensitivity of the plantar surface of the paw
was measured by dynamic plantar aesthesiometry (DPA,
Ugo Basile 37400, Comerio, Italy). Mechanonociceptive
thresholds were expressed in gram (g) [44, 47].
Measurement of paw swelling
Paw volume was measured by plethysmometry (Ugo
Basile Plethysmometer 7140, Comerio, Italy), and was
expressed in cubic centimeter (cm3) [44, 47].
Measurement of thermal hypersensitivity
The thermonociceptive threshold of the paw was
determined on an increasing-temperature hot plate
(IITC Life Science, Woodland Hills, CA, USA) heated
up from 30 °C at a rate of 12 °C/min until the animal
either exhibited nocifensive responses (lifting, shaking
or licking either hindpaw) or the maximum value (53 °C)
was reached. Hypersensitivity was expressed in °C drop of
thermonociceptive threshold compared to the control
values [48].
Measurement of cold sensitivity of the paw
The cold sensitivity was determined by the withdrawal
latency after immersing the hindpaw in 0 °C water. It
was expressed as withdrawal latency decrease compared
to the control values [49].
Measurement of knee diameter
The anteroposterior and mediolateral diameter of the
knee joints were measured with a digital micrometer
(Mitutoyo Corporation, Kawasaki, Japan). Knee joint
thickness was expressed in millimeter (mm) [42].
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Measurement of spontaneous weight distribution
Spontaneous weight bearing on the two hindlimbs was de-
termined by an incapacitance tester (Linton Instrumentation,
Diss, England). The percentage of weight distributed on
the ipsilateral hindlimb ([weight on the right hindlimb/
(weight on the left + weight on the right)] x 100) was
compared before and after the MIA administration [50].
In vivo bioluminescence imaging of myeloperoxidase
Neutrophil myeloperoxidase (MPO) activity was assessed
with luminol-derived bioluminescence. Luminol (5-amino-
2,3-dihydro-1,4-phthalazinedione) sodium salt (150 mg/kg,
Gold Biotechnology, Olivette, MO, USA) dissolved in sterile
phosphate-buffered saline (PBS, 20 mg/ml) was injected
intraperitoneally into anaesthetized mice (100/10 mg/kg
ketamine-xylazine i.p.) on days 2 and 7 post CFA adminis-
tration. Bioluminescence imaging was performed
10 minutes post injection using the IVIS Lumina II
(PerkinElmer, Waltham, MA, USA; 60s acquisition,
f/stop = 1, binning = 8). Identical regions of interest
(ROIs) were applied around the ankles and lumines-
cence was expressed as total radiance (total photon
flux/s) [51, 52].
In vivo fluorescence imaging of vascular leakage
Vascular leakage was visualized on indocyanine green
(ICG)-based fluorescence imaging. ICG (0.5 mg/kg,
Sigma-Aldrich, St. Louis, MO, USA) dissolved in Kolli-
phor HS 15 (Sigma-Aldrich, St. Louis, MO, USA) was
injected intravenously into anaesthetized mice (100/
10 mg/kg ketamine-xylazine i.p.) on days 2 and 7 follow-
ing CFA administration. Fluorescence imaging was per-
formed 20 minutes post injection using the IVIS Lumina
II (PerkinElmer, Waltham, MA, USA; auto acquisition
time, f/stop = 1, binning = 2, excitation: 745 nm, emis-
sion filter: >800 nm). Data were analyzed and ROIs were
drawn around the ankle joints. Fluorescence was
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Fig. 1 Attenuated CFA-induced chronic mechanical hypersensitivity and oedema in TRPA1 KO mice. CFA-evoked (a) mechanical hypersensitivity
(n = 14–17/group), (b) oedema (n = 14–17/group), (c) thermal hypersensitivity (n = 7–8/group), and (d) cold sensitivity (n = 7–8/group) of the hindpaw of
TRPA1 KO mice as compared to their WT counterparts throughout the 21-day experimental period. Data are shown as means ± SEM, *p< 0.05, **p< 0.01,
***p< 0.001 (vs. WT ipsilateral paw), ###p< 0.001 (vs. respective contralateral paw); two-way ANOVA followed by Bonferroni’s multiple comparison test.
ANOVA analysis of variance, CFA complete Freund’s adjuvant, KO knockout, SEM standard error of the mean, TRPA1 transient receptor potential akyrin 1,
WT wildtype
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expressed as total radiant efficiency ([photons/s/cm2/sr]/
[μW/cm2]) [51].
Histology and evaluation of joint inflammation
Animals were terminally anaesthetized using sodium
pentobarbital (50 mg/kg, i.p.). They were euthanized
10 days after CFA (the maximum point of the inflamma-
tion) and 22 days after MIA administration (the peak of
the tissue damage). Ankle and knee joints were excised,
fixed in formaldehyde, decalcified, dehydrated, embed-
ded in paraffin, sliced into sections (3–5 μM) and
stained with hematoxylin and eosin or Safranin O for
detecting collagen depositions and fibroblasts [44, 47].
Arthritic changes were scored by an observer blinded
from the study. CFA-induced histopathological changes
were scored using a scale of 0 to 3 according to (1) infil-
tration of mononuclear cells into the areolar tissue, (2)
synovial cell lining hyperplasia, and (3) cartilage destruc-
tion. The scores for each of the three criteria were accu-
mulated to generate a composite arthritis score ranging
between 0 and 9. MIA-induced histological changes
were characterized with a modified Mankin semiquanti-
tative scoring system and additional parameters [53–55].
The Mankin score assesses structure (0–6), cellularity
(0–4), matrix staining (0–4), and tidemark integrity (0–1).
In addition synovial hyperplasia and synovial inflamma-
tory cells infiltration on a scale of 0 to 3 and the presence
of osteophyte formation (0–1) were scored. Mean scores
were determined from the sections of different animals,
and composite score values were calculated from these
mean scores.
Statistical analysis
Results are expressed as mean ± standard error of the
mean (SEM). Statistical evaluation was carried out by
GraphPad Prism 5 (GraphPad Software, San Diego, CA,
USA). Mechanical hypersensitivity, paw oedema, ther-
mal hypersensitivity, cold allodynia, knee joint swelling,
spontaneous weight distribution, results from biolu-
minescence and fluorescence imaging were evaluated
by repeated measures two-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple compari-
son test. In the histological study one-way ANOVA
followed by Bonferroni’s multiple comparison test were
used. In all cases p < 0.05 was considered to be
significant.
Fig. 2 Decreased CFA-evoked neutrophil myeloperoxidase activity and vascular leakage in the ankle joints of TRPA1 KO mice. a Representative images
of luminol activity showing neutrophil myeloperoxidase activity, and (b) quantification of luminescence in the diseased joints on days 2
and 7. c Representative images of indocyanine green fluorescence demonstrating plasma protein extravasation in the ipsilateral joints, and
(d) quantitative analysis of the fluorescence intensity at the same time points. Data are shown as means ± SEM of n = 5–7 mice/group,
*p < 0.05, ***p < 0.001 (vs. WT ipsilateral joint), #p < 0.05, ###p < 0.001 (vs. respective contralateral joint); two-way ANOVA followed by Bonferroni’s multiple
comparison test. ANOVA analysis of variance, CFA complete Freund’s adjuvant, KO knockout, SEM standard error of the mean, TRPA1 transient receptor
potential akyrin 1, WT wildtype
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Results
CFA-induced mechanical hypersensitivity and paw
oedema are attenuated in TRPA1-deficient mice
In WT animals an approximate 60 % decrease of the
mechanonociceptive thresholds developed 1 day after the
adjuvant injection (from 8.19 ± 0.13 g to 3.21 ± 0.29 g),
which gradually decreased to 40 % (4.88 ± 0.33 g) by the
end of the study. Significantly reduced mechanical
hypersensitivity was observed in the TRPA1-deleted group
starting on day 2 of the experiment (Fig. 1a). Considerable
hindpaw oedema developed in WT mice after the
induction of arthritis reaching a maximal swelling of
approximately 83 % on day 14 (from 0.09 ± 0.001 cm3
to 0.18 ± 0.005 cm3). The oedema was significantly
smaller in TRPA1 KO animals with a maximum of
54 % (0.15 ± 0.005 cm3; Fig. 1b). The thermonocicep-
tive thresholds of the inflamed paws of both WT and
TRPA1 KO mice were similar to the baseline values
of naive mice (WT: 40.78 ± 0.09 °C vs. TRPA1 KO:
39.79 ± 0.36 °C; Fig. 1c). The time spent in 0 °C water
did not differ basically between the TRPA1 KO and WT
mice (WT ipsilateral paw: 121.71 ± 4.44 sec vs. TRPA1
KO ipsilateral paw: 132.56 ± 5.46 sec; WT contralateral
paw: 124.36 ± 6.37 sec vs. TRPA1 KO contralateral paw:
136.81 ± 4.56 sec). Cold tolerance similarly decreased in
all groups during the experimental period independently
of the inflammation suggesting hypersensitivity induced
by the repeated measurements (Fig. 1d).
Neutrophil myeloperoxidase activity is reduced in the
early phase and vascular leakage is decreased in the late
stage of the arthritis in TRPA1 KO animals
Luminol-derived bioluminescence revealed an increase
in neutrophil-derived MPO activity in the arthritic ankle
joints of both groups, being significantly smaller in the
KO strain in the early phase (day 2) (Fig. 2a). The fluor-
escence was similarly high in the ankle joints of both
groups in the early phase, demonstrating a remarkable
enhancement of plasma extravasation. In the late phase
(day 7), plasma extravasation diminished in both groups
compared to the early phase, but significant difference
was detected in TRPA1 KO mice (Fig. 2b).
CFA-induced histopathological severity was reduced in
the tibiotarsal joint of TRPA1 KO mice
The tibiotarsal joints of WT mice showed remarkably
enhanced inflammatory cell infiltration into the areolar tis-
sue, marked synovial cell lining hyperplasia and minimal
cartilage destruction (Fig. 3c). In contrast, TRPA1-deficient
mice showed reduced infiltration of inflammatory cells into
Fig. 3 Decreased severity of CFA-induced histopathological alterations in the tibiotarsal joint of TRPA1 KO mice. Representative slides stained with
hematoxylin and eosin of (a) an intact tibiotarsal joint of a WT, (c) arthritic WT, and (d) arthritic TRPA1 KO mouse obtained on day 10 (40× magnification;
mononuclear cell infiltration (mci), synovial cell lining hyperplasia (sh)). b Semiquantitative composite arthritis scores obtained on the basis of synovial cell
lining hyperplasia, mononuclear cell infiltration and cartilage destruction. Box plots represent medians of composite scores for n = 4–5
mice/group; ***p < 0.001 (vs. WT ipsilateral joint), ###p < 0.001 (vs. respective contralateral joint); one-way ANOVA followed by Bonferroni’s
multiple comparison test. ANOVA analysis of variance, CFA complete Freund’s adjuvant, KO knockout, TRPA1 transient receptor potential
akyrin 1, WT wildtype
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the areolar tissue and moderate hyperplasia of the synovial
cell lining, but cartilage damage was not detected (Fig. 3d).
Semiquantitative scoring of composite arthritic changes in
CFA-injected tibiotarsal joints found the severity of
arthritis was significantly decreased in KO animals (WT
ipsilateral joint: 4.4 ± 0.19 vs. TRPA1 KO ipsilateral joint:
2.63 ± 0.43) (Fig. 3b).
MIA-induced pain behaviour was decreased in
TRPA1-deleted mice
The basal mechanonociceptive thresholds were 7.42 ± 0.1 g
and 7.51 ± 0.13 g in the WT and TRPA1 KO groups, re-
spectively. MIA injection induced a 27–52 % drop of the
mechanonociceptive threshold in WT mice and 30–43 %
in the KO animals. However, reduced hypersensitivity was
measured in the TRPA1 KO group from the 3rd to the 11th
day, the difference between the two groups was significant
on the 3rd and 8th days of the study (Fig. 4a).
MIA-induced reduction in weight bearing of the ipsilat-
eral limb indicates the development of spontaneous pain.
Significantly less decrease of weight distribution was ob-
served in TRPA1 KO mice on the 2nd, 6th and 10th days
compared to their WTcontrols (Fig. 4b).
MIA evoked a remarkable oedema of the knee joint in
both WTand TRPA1 KO mice. The maximal swelling was
detected 6 hours after the injection measured medio-
laterally (WT: from 3.99 ± 0.06 mm to 5.34 ± 0.151 mm,
TRPA1 KO: from 4.15 ± 0.05 mm to 5.40 ± 0.09 mm).
Then swelling decreased gradually from the 2nd day in
both groups (Fig. 4c-d).
Histopathological severity did not differ between the
MIA-injected knees of TRPA1 KO and WT mice
The MIA-injected knee joints of both WT and TRPA1
KO mice showed similar pictures: roughened cartilage
surface, moderate disorganization and cell loss, reduced
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Fig. 4 Decreased MIA-induced pain behaviours in TRPA1 KO mice. MIA-evoked (a) mechanical hypersensitivity, (b) percentage of spontaneous
weight distribution and (c-d) mediolateral and anteroposterior diameters of the ipsilateral knee joints of TRPA1 KO mice as compared to their WT
counterparts throughout the 21-day experimental period. Results are shown as means ± SEM of n = 10–15 mice/group, *p < 0.05 (vs. WT ipsilateral
limb), #p < 0.05, ###p < 0.001 (vs. respective contralateral limb), two-way ANOVA followed by Bonferroni’s multiple comparison test. ANOVA analysis
of variance, KO knockout, MIA monosodium iodoacetate, SEM standard error of the mean, TRPA1 transient receptor potential akyrin 1, WT wildtype
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matrix staining, often disrupted tidemark integrity
(Fig. 5a-d).
Similar mechanical hypersensitivity, paw oedema, thermal
hypersensitivity and cold sensitivity were detected in WT
and TRPA1 KO mice after carrageenan administration
Similar mechanical hypersensitivity developed in the
carrageenan-injected paws both in the WT and TRPA1
KO groups 1 hour after the injection, the mechanonoci-
ceptive threshold decreased from 7.96 ± 0.19 g to 3.78 ±
0.38 g and 8.11 ± 0.15 g to 3.35 ± 0.39 g, respectively
(Fig. 6a).
An approximate 60 % paw oedema developed 1 hour
after the carrageenan administration in both groups
(WT: from 0.09 ± 0.001 cm3 to 0.15 ± 0.005 cm3, TRPA1
KO: from 0.09 ± 0.001 cm3 to 0.14 ± 0.005 cm3), reached
the maximum of 85–95 % at the 23-hour time point
(Fig. 6b).
The noxious heat threshold decreased by the carra-
geenan administration after 1 hour in both groups, then
returned to the control values (WT: 46.74 ± 0.28 °C vs.
TRPA1 KO: 46.66 ± 0.29 °C, Fig. 6c). The time spent in
0 °C water decreased to 50 % compared to the initial
values in both groups (Fig. 6d).
Mechanical hypersensitivity and oedema similarly
developed in CFA-induced acute knee joint inflammation
of TRPA1 KO and WT mice
Four hours after CFA injection, the mechanonociceptive
thresholds of the ipsilateral limbs decreased similarly by
30 % (WT: from 7.30 ± 0.22 g to 5.25 ± 0.30 g, TRPA1 KO:
from 7.24 ± 0.13 g to 5.12 ± 0.35 g), and reached its max-
imum of 40–50 % at the 8-hour time point remaining
stable for the total 24-hour duration of the study (Fig. 7a).
CFA induced remarkable swelling of the knee joints in
both groups with no significant difference. The mediolat-
eral and anteroposterior diameters increased gradually by
10–15 % at the 24-hour time point (mediolateral: WT:
from 3.85 ± 0.02 mm to 4.29 ± 0.08 mm, TRPA1 KO: from
3.92 ± 0.061 mm to 4.44 ± 0.09 mm; anteroposterior:
WT: from 4.45 ± 0.05 mm to 5.10 ± 0.10 mm vs. KO:
from 4.54 ± 0.09 mm to 5.15 ± 0.16 mm) (Fig. 7b-c).
Discussion
These results showed that chronic arthritis/osteoarthritis
and related pain behaviours are mediated by the TRPA1
receptor activation. Adjuvant-induced oedema and in-
flammatory mechanical hypersensitivity, as well as MIA-
evoked degenerative mechanical hypersensitivity with a
potential neuropathic component and reduced weight
Fig. 5 Similar histopathological severity of the MIA-injected knees of TRPA1 KO and WT mice. Representative slides stained with Safranin O of
(a) an intact knee joint, (c) osteoarthritic WT, and (d) TRPA1 KO mouse knee obtained on day 22 (200× magnification; roughened cartilage surface
(cs), moderate disorganization and cell loss (cl), reduced matrix staining (ms), disrupted tidemark integrity (ti)). b Modified Mankin semiquantitative
scores obtained on the basis of structure, cellularity, matrix staining, tidemark integrity, synovial hyperplasia, synovial inflammatory cells infiltration,
and osteophyte formation. Box plots represent medians of composite scores for n = 6–9 mice/group; ###p < 0.001 (vs. respective contralateral joint),
one-way ANOVA followed by Bonferroni’s multiple comparison test. ANOVA analysis of variance, KO knockout, MIA monosodium iodoacetate,
TRPA1 transient receptor potential akyrin 1, WT wildtype
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bearing are diminished in TRPA1 KO mice. Further-
more, we presented the first evidence that TRPA1 is in-
volved in the early neutrophil activation and late plasma
extravasation in the CFA arthritis model. In contrast to
some data indicating that TRPA1 mediates carrageenan-
induced acute mechanical hypersensitivity in rats [10]
and paw oedema in mice [39], our results clearly demon-
strated that this receptor does not have a pivotal role in
acute inflammation and hypersensitivity either in the
knee joint or in the paw (Table 1).
The CFA-, MIA- and carrageenan-induced models are
widely used and well-characterized rodent models of
acute and chronic inflammation [56–60]. CFA is heat-
killed Mycobacterium tuberculosis, muramyl dipeptide
involved in the cell wall causes a Th1- and cytokine-
driven joint inflammation in rodents, which can mimic
the main pathologic features of human rheumatoid
arthritis [61–64]. It can also be used to induce acute
(1–3 days) and chronic inflammation (3 weeks). In our
chronic model TRPA1 KO mice showed significantly
decreased mechanical hypersensitivity from days 2 to 7,
attenuated oedema from the second day during the total
3-week period, and reduced arthritic changes in the tibio-
tarsal joint at the 10-day time point as compared to their
WT counterparts. Furthermore, we provided the first in
vivo bioluminescence and fluorescence imaging data that
TRPA1 activation mediates early neutrophil activation (on
day 2) and late plasma protein extravasation (on day 7) in
chronic arthritis. The regulatory role of TRPA1 receptors
in chronic arthritic pain is supported by the finding that
TRPA1 deletion hampered ongoing nociception in CFA-
induced monoarthritis [42]. However, this study found no
difference in knee joint swelling or histology, and con-
cluded that the hyperalgesic function of TRPA1 was disso-
ciated from joint swelling and inflammation [42]. These
differences can be explained by the distinct features of
these models (intra-articular vs. intraplantar/tail root
administration, localized monoarthritis in the knee joint
vs. small joints with systemic symptoms, different kin-
etics) and different investigational techniques (digital
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Fig. 6 No change of acute carrageenan-evoked hypersensitivity and paw oedema in TRPA1 KO mice. Carrageenan-induced (a) mechanical hypersensitivity
(n = 12–13/group), (b) oedema (n = 12–13/group), (c) thermal hypersensitivity (n = 12–13/group), and (d) cold sensitivity (n = 7–8/group) of
the hindpaw of TRPA1 KO mice as compared to their WT counterparts throughout the 24-hour experimental period. Data are shown as means ± SEM,
###p< 0.001 (vs. respective contralateral paw); two-way ANOVA followed by Bonferroni’s multiple comparison test. ANOVA analysis of variance, KO knockout,
MIA monosodium iodoacetate, SEM standard error of the mean, TRPA1 transient receptor potential akyrin 1, WT wildtype
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micrometer for the knee vs. plethysmometer for the
paw). The knockout studies were confirmed by
experiments with TRPA1-selective antagonists. Intra-
peritoneal, intraplantar or intrathecal injection of
HC-030031 significantly reduced the long-lasting mech-
anical hypersensitivity at the 1-, 7- and 28-day time points
[37]. The co-expression and interaction of TRPA1 and
TRPV1 in a subpopulation of peptidergic, afferent Aδ and
C fibres is well known [11, 29, 65, 66]. We previously
showed decreased mechanical hypersensitivity, paw
swelling and histopathological changes in TRPV1 KO
mice in the same CFA model [44]. These results suggest
that both TRPA1 and TRPV1 have relevant regulatory
roles in long-term inflammation and hypersensitivity.
Thermal hypersensitivity did not develop in our CFA
model, the noxious heat threshold did not significantly
change in response to the inflammatory reaction. Data
showing no difference in thermosensitivity of TRPA1 KO
and WT mice are in agreement with previous reports sug-
gesting that TRPA1 is not a heat sensor [19, 23, 38].
Meanwhile, cold sensitivity increased in all groups inde-
pendently of the inflammation suggesting the induction of
cold hypersensitivity by the repeated measurements.
Therefore, this investigational technique is not suitable for
testing nociception in this model. However, phar-
macological blockade of TRPA1 abolished CFA-evoked
nocifensive behaviour to cold stimulus determined by a
distinct methodology (1 % tetrafluoroethane spray on the
(See figure on previous page.)
Fig. 7 CFA-induced acute knee joint pain and oedema are not influenced by TRPA1 deletion. CFA-evoked acute (a) mechanical hypersensitivity,
(b-c) mediolateral and anteroposterior diameters of the ipsilateral knee joints of TRPA1 KO mice as compared to their WT counterparts throughout the
24-hour experimental period. Results are shown as means ± SEM of n = 11–12 mice/group, #p< 0.05 (vs. respective contralateral limb), two-way ANOVA
followed by Bonferroni’s multiple comparison test. ANOVA analysis of variance, CFA complete Freund’s adjuvant, KO knockout, SEM standard error of the
mean, TRPA1 transient receptor potential akyrin 1, WT wildtype
Table 1 Summary of functional and morphological alterations in different inflammation models in TRPA1 KO mice as compared to
their WTs
In TRPA1 KO mice, CFA-induced chronic mechanical hypersensitivity, paw swelling, neutrophil MPO-activation, plasma extravasation and histopathological
changes, as well as MIA-evoked mechanical hypersensitivity and spontaneous weight distribution were significantly reduced. In contrast, thermal hypersensitivity
and cold sensitivity in the chronic CFA-model, knee diameter, histopathological changes in the MIA-model, and mechanical and thermal hypersensitivity, oedema
and cold sensitivity in the carrageenan- and CFA-induced acute models did not significantly differ between the WT and KO groups
CFA complete Freund’s adjuvant, MIA monosodium iodoacetate, MPO myeloperoxidase TRPA1 transient receptor potential akyrin 1, KO knockout, WT wildtype
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hindpaw) in mice [37]. Therefore, the in vivo functional
relevance of the noxious cold activation of TRPA1 in the
processing of different pain modalities still remains an
open question.
Intra-articular injection of MIA inhibits a key enzyme
activity of glycolysis (glyceraldehye-3-phosphate dehydro-
genase) in chondrocytes leading to progressive loss of
these cells. The destruction of the articular cartilage, tran-
sient synovial inflammation and pain behaviour are similar
to the human OA [67–71]. MIA results in decreased
weight bearing on the injured limb, movement-evoked
pain and hypersensitivity [72, 73]. Previous data showed
that chronic joint pain originates from the periphery by
the sensitization of primary afferent nerves [74–77]. It is
well-known, that TRPA1 receptors are highly expressed
on these fibres, but whether these receptors have a role in
OA was investigated only with a selective receptor antag-
onist [40, 41]. Since systemic or intra-articular HC-030031
failed to block pain-related behaviours 1 hour post injec-
tion [40], and the blockade of TRPA1 did not reduce the
MIA-induced spontaneous firing of sensory neurons [41],
it could be concluded that MIA-induced ongoing pain is
independent of TRPA1. Our present results with knockout
mice support this concept regarding the knee joint swell-
ing and histopathological alterations. However, we found
that TRPA1 contributes to MIA-evoked decreased weight
bearing and tactile hypersensitivity between days 3 and 10
of the experimental period.
Intraplantar or intra-articular injection of carrageenan
is an appropriate acute technique for testing anti-
inflammatory drugs [56]. It involves both neurogenic
and non-neurogenic mechanisms characterized by pros-
taglandin production, cyclooxygenase (COX)-2 up-
regulation, formation of reactive nitrogen and oxygen
species, as well as cytokines and other inflammatory me-
diators [78–82]. In the present study we showed that
TRPA1 does not have a role in acute carrageenan-
induced paw oedema, mechanical and thermal hypersen-
sitivity. In contrast, previous reports demonstrated that
the selective TRPA1-antagonist HC-030031 and/or genetic
deletion of TRPA1 inhibited the development and main-
tenance of carrageenan-induced inflammatory hypersensi-
tivity in rats [10], and paw oedema in mice at the 3- and
6-hour time points [39], respectively. Distinct species,
measuring time points, volumes, concentrations, and in-
vestigational techniques might be possible explanations
for the differences. Similarly to what we found in TRPA1
KO mice, we previously described no difference in the car-
rageenan model in TRPV1-deficient mice [46].
Similarly to the carrageenan model, acute intra-
articular CFA-evoked mechanical hypersensitivity and
swelling were not altered by the deletion of the TRPA1
receptor over a 24-hour period, which is in agreement
with previous reports [36, 42].
The distinct functional outcomes between the roles of
the TRPA1 receptor in our four models can be explained
by the wide distribution of TRPA1 on sensory nerves and
non-neuronal cells, such as keratinocytes [12], fibroblasts
[13], synoviocytes [14], macrophages [15, 16], lymphocytes
[17], thymocytes [17] and endothelial cells [18]. Keratino-
cytes stimulated by TRPA1 agonist have been shown to in-
crease the expression and release of pro-inflammatory
interleukins [12], which can activate or sensitize sensory
nerve endings [83]. The exposure of thymocytes to cinna-
maldehyde accelerated T cell differentiation [17], which has
a crucial role in the pathomechanism of CFA-induced arth-
ritis. Macrophages, the other key players of CFA-evoked
joint inflammation, also express TRPA1 mediating anti-
inflammatory effects [15, 16]. Furthermore, there is a broad
range of endogenous TRPA1 agonists produced locally dur-
ing inflammatory processes that might differently modulate
the receptor on the sensory nerves and non-neural struc-
tures. This would consequently trigger and/or inhibit the
inflammatory cascades.
Conclusions
Our findings demonstrate an important regulatory role
of the TRPA1 receptor in chronic arthritis/osteoarthritis
and related pain behaviours in the mouse. Therefore, it
might be a promising target for novel analgesic/anti-in-
flammatory drugs.
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